{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:09:40Z","timestamp":1784387380448,"version":"3.55.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11498-3","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:33:21Z","timestamp":1770615201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oncolytic human herpesvirus for cancer therapy"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-8742","authenticated-orcid":false,"given":"Melisa Beyhan","family":"Y\u0131lmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9358-8103","authenticated-orcid":false,"given":"Dilek","family":"Muz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"11498_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin D, Shen Y, Liang T (2023) Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther 8:156. https:\/\/doi.org\/10.1038\/s41392-023-01407-6","journal-title":"Signal Transduct Target Ther"},{"issue":"25","key":"11498_CR2","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Coffin RS (2015) Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780\u20132788. https:\/\/doi.org\/10.1200\/JCO.2014.58.3377","journal-title":"J Clin Oncol"},{"issue":"7","key":"11498_CR3","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/v13071408","volume":"13","author":"C Kangas","year":"2021","unstructured":"Kangas C, Krawczyk E, He B (2021) Oncolytic HSV: underpinnings of tumor susceptibility. Viruses 13(7):1408. https:\/\/doi.org\/10.3390\/v13071408","journal-title":"Viruses"},{"issue":"6","key":"11498_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004762","volume":"10","author":"F Ju","year":"2022","unstructured":"Ju F, Luo Y, Lin C, Jia X, Xu Z, Tian R, Lin Y, Zhao M, Chang Y, Huang X, Li S, Ren W, Qin Y, Yu M, Jia J, Han J, Luo W, Zhang J, Fu G, Ye X, Huang C, Xia N (2022) Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. J Immunother Cancer 10(6):e004762. https:\/\/doi.org\/10.1136\/jitc-2022-004762","journal-title":"J Immunother Cancer"},{"issue":"6","key":"11498_CR5","doi-asserted-by":"publisher","first-page":"vi4","DOI":"10.1093\/neuonc\/noz175.014","volume":"21","author":"T Todo","year":"2019","unstructured":"Todo T (2019) ATIM-14: results of phase II clinical trial of oncolytic herpes virus G47\u2206 in patients with glioblastoma. Neurooncol 21(6):vi4. https:\/\/doi.org\/10.1093\/neuonc\/noz175.014","journal-title":"Neurooncol"},{"issue":"12","key":"11498_CR6","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1586\/14737140.2015.1115725","volume":"15","author":"KJ Harrington","year":"2015","unstructured":"Harrington KJ, Puzanov I, Hecht JR, Hodi FS, Szabo Z, Murugappan S, Kaufman HL (2015) Clinical development of talimogene Laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther 15(12):1389\u20131403. https:\/\/doi.org\/10.1586\/14737140.2015.1115725","journal-title":"Expert Rev Anticancer Ther"},{"key":"11498_CR7","unstructured":"International Committee on Taxonomy of Viruses (ICTV) (2023) Virus Taxonomy: 2023 Release \u2013 Genus: Simplexvirus. https:\/\/ictv.global\/report\/chapter\/orthoherpesviridae\/orthoherpesviridae"},{"issue":"6","key":"11498_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13060572","volume":"13","author":"PAC Maple","year":"2025","unstructured":"Maple PAC, Hosseini AA (2025) Human alpha herpesviruses infections (HSV1, HSV2, and VZV), Alzheimer\u2019s disease, and the potential benefits of targeted treatment or vaccination\u2014a virological perspective. Vaccines 13(6):572. https:\/\/doi.org\/10.3390\/vaccines13060572","journal-title":"Vaccines"},{"issue":"30","key":"11498_CR9","doi-asserted-by":"publisher","first-page":"21348","DOI":"10.18632\/oncotarget.25096","volume":"9","author":"X Fu","year":"2018","unstructured":"Fu X, Tao L, Wang PY, Cripe TP, Zhang X (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9(30):21348\u201321358. https:\/\/doi.org\/10.18632\/oncotarget.25096","journal-title":"Oncotarget"},{"key":"11498_CR10","doi-asserted-by":"publisher","unstructured":"Agarwalla PK, Aghi MK (2012) Oncolytic herpes simplex virus engineering and preparation. In Methods in Molecular Biology (Vol. 797, pp. 1\u201319). https:\/\/doi.org\/10.1007\/978-1-61779-340-0_1","DOI":"10.1007\/978-1-61779-340-0_1"},{"issue":"18","key":"11498_CR11","doi-asserted-by":"publisher","first-page":"9862","DOI":"10.1128\/jvi.77.18.9862-9871.2003","volume":"77","author":"WW Newcomb","year":"2003","unstructured":"Newcomb WW, Thomsen DR, Homa FL, Brown JC (2003) Assembly of the herpes simplex virus capsid: identification of soluble scaffold-portal complexes and their role in formation of portal-containing capsids. J Virol 77(18):9862\u20139871. https:\/\/doi.org\/10.1128\/jvi.77.18.9862-9871.2003","journal-title":"J Virol"},{"issue":"10","key":"11498_CR12","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3390\/v13101913","volume":"13","author":"EB Draganova","year":"2021","unstructured":"Draganova EB, Valentin J, Heldwein EE (2021) The ins and outs of herpesviral capsids: divergent structures and assembly mechanisms across the three subfamilies. Viruses 13(10):1913. https:\/\/doi.org\/10.3390\/v13101913","journal-title":"Viruses"},{"issue":"13","key":"11498_CR13","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.1128\/MCB.20.13.4922-4931.2000","volume":"20","author":"PM Ojala","year":"2000","unstructured":"Ojala PM, Sodeik B, Ebersold MW, Kutay U, Helenius A (2000) Herpes simplex virus type 1 entry into host cells: reconstitution of capsid binding and uncoating at the nuclear pore complex in vitro. Mol Cell Biol 20(13):4922\u20134931. https:\/\/doi.org\/10.1128\/MCB.20.13.4922-4931.2000","journal-title":"Mol Cell Biol"},{"issue":"7","key":"11498_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00504-25","volume":"99","author":"A Stevens","year":"2025","unstructured":"Stevens A, Kashyap S, Crofut E, Alvarez-Cabrera AL, Jih J, Liu Y-T, Zhou ZH (2025) Structure of a new capsid form and comparison with A-, B-, and C-capsids clarify herpesvirus assembly. J Virol 99(7):e0050425. https:\/\/doi.org\/10.1128\/jvi.00504-25","journal-title":"J Virol"},{"issue":"1","key":"11498_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/mt.2008.228","volume":"17","author":"JM Markert","year":"2009","unstructured":"Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY (2009) Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM. Mol Ther 17(1):199\u2013207. https:\/\/doi.org\/10.1038\/mt.2008.228","journal-title":"Mol Ther"},{"issue":"12","key":"11498_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/gt.2008.72","volume":"15","author":"TC Liu","year":"2008","unstructured":"Liu TC, Kirn D (2008) Gene therapy progress and prospects: oncolytic viruses for cancer. Gene Ther 15(12):877\u2013884. https:\/\/doi.org\/10.1038\/gt.2008.72","journal-title":"Gene Ther"},{"issue":"2","key":"11498_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2013.220","volume":"22","author":"ST Workenhe","year":"2014","unstructured":"Workenhe ST, Mossman KL (2014) Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther 22(2):251\u2013256. https:\/\/doi.org\/10.1038\/mt.2013.220","journal-title":"Mol Ther"},{"key":"11498_CR18","doi-asserted-by":"publisher","unstructured":"Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin,O., \u2026 Allison, J. P. (2017). Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell, 170(6), 1109\u20131119.e10. https:\/\/doi.org\/10.1016\/j.cell.2017.08.034","DOI":"10.1016\/j.cell.2017.08.034"},{"key":"11498_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1549349","volume":"16","author":"SM Schneider","year":"2025","unstructured":"Schneider SM, Tebaldi G, Gianopulos KA, Weed DJ, Pritchard SM, Leach C, Nicola AV (2025) Herpes simplex virus 1 glycoprotein C promotes virus penetration from endosomes during entry, independent of interaction with heparan sulfate. Frontiers in Microbiology 16:1549349. https:\/\/doi.org\/10.3389\/fmicb.2025.1549349","journal-title":"Frontiers in Microbiology"},{"key":"11498_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.617578","volume":"10","author":"K Madavaraju","year":"2021","unstructured":"Madavaraju K, Koganti R, Volety I, Yadavalli T, Shukla D (2021) Herpes simplex virus cell entry mechanisms: an update. Frontiers in Cellular and Infection Microbiology 10:617578. https:\/\/doi.org\/10.3389\/fcimb.2020.617578","journal-title":"Frontiers in Cellular and Infection Microbiology"},{"issue":"11","key":"11498_CR21","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.addr.2003.07.006","volume":"55","author":"JA Garner","year":"2003","unstructured":"Garner JA (2003) Herpes simplex virion entry into and intracellular transport within mammalian cells. Adv Drug Deliv Rev 55(11):1497\u20131513. https:\/\/doi.org\/10.1016\/j.addr.2003.07.006","journal-title":"Adv Drug Deliv Rev"},{"key":"11498_CR22","doi-asserted-by":"publisher","unstructured":"D\u00f6hner K, Sodeik B (2005) The role of the cytoskeleton during viral infection. Current Topics in Microbiology and Immunology (Vol. 285, pp. 67\u2013108). https:\/\/doi.org\/10.1007\/3-540-26764-6_3","DOI":"10.1007\/3-540-26764-6_3"},{"issue":"1","key":"11498_CR23","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/cancers3010994","volume":"3","author":"T Ozaki","year":"2011","unstructured":"Ozaki T, Nakagawara A (2011) Role of p53 in cell death and human cancers. Cancers (Basel) 3(1):994\u20131013. https:\/\/doi.org\/10.3390\/cancers3010994","journal-title":"Cancers (Basel)"},{"key":"11498_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-103","volume":"12","author":"DL Bartlett","year":"2013","unstructured":"Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS (2013) Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 12:103. https:\/\/doi.org\/10.1186\/1476-4598-12-103","journal-title":"Mol Cancer"},{"issue":"1","key":"11498_CR25","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1080\/21505594.2021.1968125","volume":"12","author":"S Zhu","year":"2021","unstructured":"Zhu S, Viejo-Borbolla A (2021) Pathogenesis and virulence of herpes simplex virus. Virulence 12(1):2670\u20132702. https:\/\/doi.org\/10.1080\/21505594.2021.1968125","journal-title":"Virulence"},{"issue":"1","key":"11498_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-020-01463-2","volume":"17","author":"W Zheng","year":"2020","unstructured":"Zheng W, Xu Q, Zhang Y, E X, Gao W, Zhang M, Zhai W, Rajkumar RS, Liu Z (2020) Toll-like receptor-mediated innate immunity against Herpesviridae infection: a current perspective on viral infection signaling pathways. Virol J 17(1):192. https:\/\/doi.org\/10.1186\/s12985-020-01463-2","journal-title":"Virol J"},{"issue":"2","key":"11498_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nri2937","volume":"11","author":"SR Paludan","year":"2011","unstructured":"Paludan SR, Bowie AG, Horan KA, Fitzgerald KA (2011) Recognition of herpesviruses by the innate immune system. Nat Rev Immunol 11(2):143\u2013154. https:\/\/doi.org\/10.1038\/nri2937","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"11498_CR28","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/sj.cgt.7700537","volume":"9","author":"S Arghese","year":"2002","unstructured":"Arghese S, Rabkin SD (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 9(12):967\u2013978. https:\/\/doi.org\/10.1038\/sj.cgt.7700537","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"11498_CR29","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1128\/jvi.76.6.2780-2788.2002","volume":"76","author":"J Melchjorsen","year":"2002","unstructured":"Melchjorsen J, Pedersen FS, Mogensen SC, Paludan SR (2002) Herpes simplex virus selectively induces expression of the CC chemokine RANTES\/CCL5 in macrophages through a mechanism dependent on PKR and ICP0. J Virol 76(6):2780\u20132788. https:\/\/doi.org\/10.1128\/jvi.76.6.2780-2788.2002","journal-title":"J Virol"},{"issue":"12","key":"11498_CR30","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1158\/2326-6066.CIR-18-0014","volume":"6","author":"MG Ghonime","year":"2018","unstructured":"Ghonime MG, Cassady KA (2018) Combination therapy using ruxolitinib and oncolytic HSV renders resistant MPNSTs susceptible to virotherapy. Cancer Immunol Res 6(12):1499\u20131510. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0014","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"11498_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071932","volume":"8","author":"K Okemoto","year":"2013","unstructured":"Okemoto K, Wagner B, Meisen H, Haseley A, Kaur B, Chiocca EA (2013) STAT3 activation promotes oncolytic HSV1 replication in glioma cells. PLoS One 8(8):e71932. https:\/\/doi.org\/10.1371\/journal.pone.0071932","journal-title":"PLoS One"},{"issue":"1","key":"11498_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00199-7","volume":"5","author":"L Bai","year":"2024","unstructured":"Bai L, Xu J, Zeng L, Zhang L, Zhou F (2024) A review of HSV pathogenesis, vaccine development, and advanced applications. Mol Biomed 5(1):35. https:\/\/doi.org\/10.1186\/s43556-024-00199-7","journal-title":"Mol Biomed"},{"issue":"34","key":"11498_CR33","doi-asserted-by":"publisher","first-page":"12873","DOI":"10.1073\/pnas.0605496103","volume":"103","author":"G Fulci","year":"2006","unstructured":"Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, Kaur B, Louis DN, Weissleder R, Caligiuri MA, Chiocca EA (2006) Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A 103(34):12873\u201312878. https:\/\/doi.org\/10.1073\/pnas.0605496103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11498_CR34","doi-asserted-by":"publisher","first-page":"304","DOI":"10.20517\/jtgg.2021.27","volume":"5","author":"F Warricker","year":"2021","unstructured":"Warricker F, Khakoo SI, Blunt MD (2021) The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma. J Transl Genet Genomics 5:304\u2013322. https:\/\/doi.org\/10.20517\/jtgg.2021.27","journal-title":"J Transl Genet Genomics"},{"issue":"14","key":"11498_CR35","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.1158\/1078-0432.CCR-14-3118","volume":"21","author":"WH Meisen","year":"2015","unstructured":"Meisen WH, Wohleb ES, Jaime-Ramirez AC, Bolyard C, Yoo JY, Russell L, Hardcastle J, Dubin S, Muili K, Yu J, Caligiuri M, Godbout J, Kaur B (2015) The impact of macrophage- and microglia-secreted TNF\u03b1 on oncolytic HSV-1 therapy in the glioblastoma tumor microenvironment. Clin Cancer Res 21(14):3274\u20133285. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3118","journal-title":"Clin Cancer Res"},{"issue":"3","key":"11498_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2249.2005.02927.x","volume":"142","author":"N Novak","year":"2005","unstructured":"Novak N, Peng WM (2005) Dancing with the enemy: the interplay of herpes simplex virus with dendritic cells. Clin Exp Immunol 142(3):405\u2013410. https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02927.x","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"11498_CR37","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1084\/jem.20030162","volume":"198","author":"J Lund","year":"2003","unstructured":"Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A (2003) Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 198(3):513\u2013520. https:\/\/doi.org\/10.1084\/jem.20030162","journal-title":"J Exp Med"},{"key":"11498_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cytogfr.2018.03.006","volume":"41","author":"JF de Graaf","year":"2018","unstructured":"de Graaf JF, de Vor L, Fouchier RAM, van den Hoogen BG (2018) Armed oncolytic viruses: a kick-start for anti-tumor immunity. Cytokine Growth Factor Rev 41:28\u201339. https:\/\/doi.org\/10.1016\/j.cytogfr.2018.03.006","journal-title":"Cytokine Growth Factor Rev"},{"issue":"9","key":"11498_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148300","volume":"131","author":"JR Gehlhausen","year":"2021","unstructured":"Gehlhausen JR, Iwasaki A (2021) B cells join T cell clusters in the host response to recurrent herpes simplex virus 2 infection. J Clin Invest 131(9):e148300. https:\/\/doi.org\/10.1172\/JCI148300","journal-title":"J Clin Invest"},{"issue":"Pt 4","key":"11498_CR40","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1099\/0022-1317-82-4-845","volume":"82","author":"AM Harandi","year":"2001","unstructured":"Harandi AM, Svennerholm B, Holmgren J, Eriksson K (2001) Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J Gen Virol 82(Pt 4):845\u2013853. https:\/\/doi.org\/10.1099\/0022-1317-82-4-845","journal-title":"J Gen Virol"},{"issue":"8","key":"11498_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1442169","volume":"7","author":"S Gujar","year":"2018","unstructured":"Gujar S, Pol JG, Kroemer G (2018) Heating it up: oncolytic viruses make tumors \u2018hot\u2019 and suitable for checkpoint blockade immunotherapies. Oncoimmunology 7(8):e1442169. https:\/\/doi.org\/10.1080\/2162402X.2018.1442169","journal-title":"Oncoimmunology"},{"issue":"8","key":"11498_CR42","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, Tanaka M (2022) Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 28(8):1630\u20131639. https:\/\/doi.org\/10.1038\/s41591-022-01897-x","journal-title":"Nat Med"},{"issue":"8062","key":"11498_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","volume":"641","author":"Y Shen","year":"2025","unstructured":"Shen Y, Bai X, Zhang Q, Liang X, Jin X, Zhao Z, Song W, Tan Q, Zhao R, Jia W, Gu S, Shi G, Zheng Z, Wei G, Wang Y, Fang T, Li Y, Wang Z, Yang Z, Guo S, Lin D, Wei F, Wang L, Sun X, Qin A, Xie L, Qiu Y, Bao W, Rahimian S, Singh M, Murad Y, Shang J, Chu M, Huang M, Ding J, Chen W, Ye Y, Chen Y, Li X, Liang T (2025) Oncolytic virus VG161 in refractory hepatocellular carcinoma. Nature 641(8062):503\u2013511. https:\/\/doi.org\/10.1038\/s41586-025-08717-5","journal-title":"Nature"},{"key":"11498_CR44","doi-asserted-by":"publisher","unstructured":"Estevez-Ordonez, D., Stein, J., Maleknia, P., Gallegos, C., Atchley, T., Laskay, N.,\u2026 Markert, J. (2023). Phase I clinical trial of oncolytic HSV-1 M032, a second-generation virus armed to express IL-12, for the treatment of adult patients with recurrent or progressive malignant glioma. Neuro-Oncology, 25(Suppl 5), v64. https:\/\/doi.org\/10.1093\/neuonc\/noad179.0253","DOI":"10.1093\/neuonc\/noad179.0253"},{"issue":"2","key":"11498_CR45","doi-asserted-by":"publisher","DOI":"10.3171\/2020.12.FOCUS20855","volume":"50","author":"DD Monie","year":"2021","unstructured":"Monie DD, Bhandarkar AR, Parney IF, Correia C, Sarkaria JN, Vile RG, Li H (2021) Synthetic and systems biology principles in the design of programmable oncolytic virus immunotherapies for glioblastoma. Neurosurg Focus 50(2):E10. https:\/\/doi.org\/10.3171\/2020.12.FOCUS20855","journal-title":"Neurosurg Focus"},{"issue":"1","key":"11498_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61275-w","volume":"10","author":"E Sasso","year":"2020","unstructured":"Sasso E, Froechlich G, Cotugno G, D\u2019Alise AM, Gentile C, Bignone V, De Lucia M, Petrovic B, Campadelli-Fiume G, Scarselli E, Nicosia A, Zambrano N (2020) <article-title update=\"added\">Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis. Sci Rep 10(1):4307. https:\/\/doi.org\/10.1038\/s41598-020-61275-w","journal-title":"Sci Rep"},{"issue":"226","key":"11498_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP (2014) Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6(226):226ra32. https:\/\/doi.org\/10.1126\/scitranslmed.3008095","journal-title":"Sci Transl Med"},{"key":"11498_CR48","doi-asserted-by":"crossref","unstructured":"Harrington KJ, Kong A, Mach N, Chesney JA, Fernandez BC, Rischin D, Cohen EEW, Radcliffe HS, Gumuscu B, Cheng J, Snyder W, Siu LL (2020) Talimogene laherparepvec and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): A multicenter, phase 1b study. Clin Cancer Res. 2020;26(19):5153\u20135161","DOI":"10.1158\/1078-0432.CCR-20-1170"},{"issue":"4","key":"11498_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043681","volume":"24","author":"G Tang","year":"2023","unstructured":"Tang G, Wang D, Zhao X, Feng Z, Chen Q, Shen Y (2023) The dilemma of HSV-1 oncolytic virus delivery: the method choice and hurdles. Int J Mol Sci 24(4):3681. https:\/\/doi.org\/10.3390\/ijms24043681","journal-title":"Int J Mol Sci"},{"issue":"3","key":"11498_CR50","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.22.00343","volume":"41","author":"JA Chesney","year":"2023","unstructured":"Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Gogas H, Hodi FS (2023) Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol 41(3):528\u2013540. https:\/\/doi.org\/10.1200\/JCO.22.00343","journal-title":"J Clin Oncol"},{"key":"11498_CR51","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41434-020-00205-x","volume":"28","author":"KJ Kim","year":"2021","unstructured":"Kim KJ, Moon D, Kong SJ, Lee YS, Yoo Y, Kim S, Kim C, Chon HJ, Kim JH, Choi KJ (2021) Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1. Gene Ther 28:186\u2013198. https:\/\/doi.org\/10.1038\/s41434-020-00205-x","journal-title":"Gene Ther"},{"issue":"2","key":"11498_CR52","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","volume":"32","author":"D Saha","year":"2017","unstructured":"Saha D, Martuza RL, Rabkin SD (2017) Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell 32(2):253-267.e5. https:\/\/doi.org\/10.1016\/j.ccell.2017.07.006","journal-title":"Cancer Cell"},{"issue":"5007","key":"11498_CR53","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.1851332","volume":"252","author":"RL Martuza","year":"1991","unstructured":"Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252(5007):854\u2013856. https:\/\/doi.org\/10.1126\/science.1851332","journal-title":"Science"},{"issue":"9","key":"11498_CR54","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14(9):642\u2013662. https:\/\/doi.org\/10.1038\/nrd4663","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"11498_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101287","volume":"15","author":"X Xie","year":"2022","unstructured":"Xie X, Lv J, Zhu W, Tian C, Li J, Liu J, Zhou H, Sun C, Hu Z, Li X (2022) The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy. Transl Oncol 15(1):101287. https:\/\/doi.org\/10.1016\/j.tranon.2021.101287","journal-title":"Transl Oncol"},{"issue":"11","key":"11498_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113158","volume":"12","author":"S Iurescia","year":"2020","unstructured":"Iurescia S, Fioretti D, Rinaldi M (2020) The innate immune signalling pathways: turning RIG-I sensor activation against cancer. Cancers (Basel) 12(11):3158. https:\/\/doi.org\/10.3390\/cancers12113158","journal-title":"Cancers (Basel)"},{"key":"11498_CR57","doi-asserted-by":"publisher","unstructured":"Wu, R., Qi, R., Xiong, H., Lei, X., Jiang, Y., He, J., \u2026 Xia, N. (2024). Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects.Signal Transduction and Targeted Therapy, 9(1), 118. https:\/\/doi.org\/10.1038\/s41392-024-01824-1","DOI":"10.1038\/s41392-024-01824-1"},{"key":"11498_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.834841","volume":"9","author":"HL Kaufman","year":"2022","unstructured":"Kaufman HL, Shalhout SZ, Iodice G (2022) Talimogene laherparepvec: moving from first-in-class to best-in-class. Front Mol Biosci 9:834841. https:\/\/doi.org\/10.3389\/fmolb.2022.834841","journal-title":"Front Mol Biosci"},{"issue":"1","key":"11498_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-01972-2","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li Y, Chen K, Qian L, Wang P (2021) Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. Cancer Cell Int 21(1):262. https:\/\/doi.org\/10.1186\/s12935-021-01972-2","journal-title":"Cancer Cell Int"},{"issue":"20","key":"11498_CR60","doi-asserted-by":"publisher","first-page":"10127","DOI":"10.1158\/0008-5472.CAN-06-2744","volume":"66","author":"T Kuroda","year":"2006","unstructured":"Kuroda T, Rabkin SD, Martuza RL (2006) Effective treatment of tumors with strong beta-catenin\/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res 66(20):10127\u201310135. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2744","journal-title":"Cancer Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11498-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11498-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11498-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:33:22Z","timestamp":1770615202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11498-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11498"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11498-3","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This review did not involve animals or human subjects and no ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"376"}}